Germany’s Merck KGaA has agreed to acquire Mirus Bio, a specialist in transfection reagents used in the production of cell and gene therapies (CGTs), in a deal valued at a
Lonza has boosted its ability to cater for customers in the fast-emerging antibody-drug conjugate category with a deal to buy Dutch company Synaffix and its platform techn